metricas
covid
Buscar en
Clinics
Toda la web
Inicio Clinics Hypothermia treatment reduced cyclin-dependent kinase 5-mediated inflammation in...
Información de la revista
Vol. 75.
(enero 2020)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 75.
(enero 2020)
COMMENTS
Open Access
Hypothermia treatment reduced cyclin-dependent kinase 5-mediated inflammation in ischemic stroke and improved outcomes in ischemic stroke patients
Visitas
738
Sombat MuengtaweepongsaI,
Autor para correspondencia
sombatm@hotmail.com

Corresponding author.
, Winchana SrivilaithonII
I Center of Excellence in Stroke, Faculty of Medicine, Thammasat University, Thailand
II Department of Emergency Medicine, Faculty of Medicine, Thammasat University, Thailand
Contenido relacionado
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

Dear Editor,

We read with interest the article by Sun et al. concerning the reduction of inflammation with therapeutic hypothermia in acute ischemic stroke (1). In this study, the authors demonstrated the improvement of inflammatory biomarkers after hypothermia treatment in both animal cerebral infarct models and patients with ischemic stroke.

Inflammation is an important step in the ischemic cascade. Therapeutic hypothermia, newly substituted by targeted temperature management (TTM), shows promising effects against the ischemic cascade via multiple mechanisms. In addition to the neuroprotective effects of TTM, their anti-inflammatory mechanism is most essential. TTM has become a standard treatment for cerebral ischemic damage due to cardiac arrest. Unfortunately, many clinical trials failed to demonstrate the benefit of TTM in ischemic stroke; therefore, the routine use of TTM in ischemic stroke is still controversial (2).

Almost all the clinical trials of TTM in ischemic stroke relied on systemic cooling with surface and endovascular methods. These two methods are effective enough to bring down the core temperature to 33°C, which is the target point of the treatment (3). This study relied on the local head cooling by one of the Chinese companies from Harbin. The details of the device were not mentioned in the manuscript. Selective brain cooling with this helmet alone had failed to demonstrate its effectiveness for hypothermic treatment (4).

The temperature measured via the tympanic membrane may be fully reflect the real temperature in the brain. In addition, the tympanic membrane is not a good site for core temperature measurement. The tympanic membrane temperature is lower than the core temperature by 0.5°C (5). The target temperature of 33 to 35°C in the tympanic membrane might not be effective for the hypothermia treatment.

The day when the NIHSS was recorded after the treatment was not mentioned in the manuscript. The NIHSS alone may not be convincing enough for clinical outcome measurement. The modified Rankin scale (mRS) at 3 months after treatment is the most reliable outcome measurement for acute ischemic stroke (6).

This study was a parallel trial in both animals and humans. The authors successfully demonstrated that the effect of neuroprotection due to anti-inflammatory mechanisms is consistent in preclinical and clinical stages. This study has an influence on the development of the future TTM trials in ischemic stroke.

REFERENCES
[1]
H Sun , J Cai , S Shen , X Ren .
Hypothermia treatment ameliorated cyclin-dependent kinase 5-mediated inflammation in ischemic stroke and improved outcomes in ischemic stroke patients.
[2]
S Muengtaweepongsa .
Methods and clinical applications of targeted temperature management.
Neurology Asia, 20 (2015), pp. 325
[3]
M Vargas , Y Sutherasan , G Servillo , P Pelosi .
What is the proper target temperature for out-of-hospital cardiac arrest?.
[4]
OA Harris , CR Muh , MC Surles , Y Pan , G Rozycki , J Macleod , et al.
Discrete cerebral hypothermia in the management of traumatic brain injury: a randomized controlled trial.
[5]
JL Moran , JV Peter , PJ Solomon , B Grealy , T Smith , W Ashforth , et al.
Tympanic temperature measurements: are they reliable in the critically ill? A clinical study of measures of agreement.
[6]
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Tissue plasminogen activator for acute ischemic stroke.

No potential conflict of interest was reported.

Copyright © 2020. CLINICS
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos